FDA approves Procysbi for nephropathic cystinosis

May 2, 2013
FDA approves procysbi for nephropathic cystinosis
Procysbi (cysteamine bitartrate) delayed-release capsules have been approved by the U.S. Food and Drug Administration to treat nephropathic cystinosis in children (6 years and up) and adults. Since it is intended to treat a rare disease or condition, Procysbi has been granted orphan product designation.

(HealthDay)—Procysbi (cysteamine bitartrate) delayed-release capsules have been approved by the U.S. Food and Drug Administration to treat nephropathic cystinosis in children (6 years and up) and adults. Since it is intended to treat a rare disease or condition, Procysbi has been granted orphan product designation.

Affecting approximately 500 patients in the United States and an estimated 3,000 worldwide, cystinosis can lead to slow body growth and small stature, weak bones, and developing and worsening . Procysbi has been approved to treat the most severe form of cystinosis—nephropathic cystinosis.

A major study involving 43 patients found Procysbi to be as effective at controlling cystine levels as Cystagon, an immediate-release tablet approved by the FDA in 1994. Recorded common side effects included gastrointestinal discomfit, bad breath, constipation, headache, drowsiness, and dizziness. More severe but less common side effects included ulcers or bleeding of the stomach or intestine, altered mental state, seizures, severe skin rashes, and allergic reactions.

"Procysbi is the only delayed-release product approved by FDA to treat nephropathic cystinosis, offering patients with this an important new treatment option," Andrew E. Mulberg, M.D., deputy director of the Division of Gastroenterology and Inborn Errors Products in the FDA's Center for and Research, said in a statement.

Procysbi is manufactured by Raptor Pharmaceuticals, based in Novato, Calif.

Explore further: FDA expands approval of Bayer cancer drug (Update)

More information: More Information

Related Stories

Iclusig approved for rare leukemias

December 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Marqibo approved for rare leukemia

August 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.